Article

Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg.

Department of Ophthalmology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Université Paris, Paris, France.
American Journal of Ophthalmology (Impact Factor: 4.02). 12/2006; 142(5):794-99. DOI: 10.1016/j.ajo.2006.06.011
Source: PubMed

ABSTRACT To prospectively compare the efficacy and safety of 4 vs 2 mg intravitreal triamcinolone acetonide (TA) injection for diabetic macular edema.
Interventional case series.

Thirty-two patients with diabetic macular edema unresponsive to laser photocoagulation.
Patients were randomly assigned to receive 4 or 2 mg intravitreal TA in one eye (16 patients in each group).
The main outcome was central macular thickness (CMT) measured by optical coherence tomography (OCT) at four, 12, and 24 weeks. Secondary outcomes were gain in Early Treatment Diabetic Retinopathy Study (ETDRS) scores, intraocular pressure (IOP), cataract progression, and duration of effect.
Before injection, mean (+/- SD) CMT was 564.5 +/- 119 microm and 522.9 +/- 148.5 microm in the 4- and 2-mg groups, respectively. At four, 12, and 24 weeks after injection, it was 275.0 +/- 79.8, 271.4 +/- 128.7, and 448.7 +/- 146.4 microm, respectively, in the 4-mg group, and 267.3 +/- 82.4, 289.8 +/- 111.4, and 394.7 +/- 178.9 microm, respectively, in the 2-mg group. At no time was the difference in CMT between both groups statistically significant (P> 0.3). The between-group differences in the gain in the ETDRS score and in IOP were not statistically significant either. Diabetic macular edema recurred after a median period of 20 weeks vs 16 weeks in the 4- and 2-mg groups, respectively (P = 0.11).
In the short term, intravitreal injection of 4 or 2 mg TA does not have different effects on CMT, visual acuity, or IOP.

1 Bookmark
 · 
78 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of diabetic macular edema is rapidly evolving. The era of laser therapy is being quickly replaced by an era of pharmacotherapy. Several pharmacotherapies have been recently developed for the treatment of retinal vascular diseases such as diabetic macular edema. Several intravitreal injections or sustained delivery devices have undergone phase 3 testing while others are currently being evaluated. The results of clinical trials have shown the superiority of some of these agents to laser therapy. However, with the availability of several of these newer agents, it may be difficult to individualize treatment options especially those patients respond differently to various therapies. As such, more effort is still needed in order to determine the best treatment regimen for a given patient. In this article, we briefly summarize the major new therapeutic additions for the treatment of diabetic macular edema and allude to some future promising therapies.
    World journal of diabetes. 12/2013; 4(6):324-338.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic macular edema (DME) is a common cause of visual impairment in diabetic patients. It is caused by an increase in the permeability of the perifoveal capillaries and a disruption of the blood retinal-barrier. The pathogenesis of DME is multifactorial. Several therapeutic modalities have been proposed for the treatment of DME. Corticosteroid treatments have emerged as an alternative therapy for persistent DME or refractory to conventional laser photocoagulation and other modalities, due to anti-inflammatory, anti-vascular endothelial growth factor and anti-proliferative effects. Many studies have demonstrated the beneficial therapeutic effect of corticosteroids with improvement to both retinal thickness and visual acuity in short-term on the treatment of DME. Peribulbar and intravitreal injections have been used to deliver steroids for DME with frequent injections due to the chronic and recurrent nature of the disease. Steroid-related side effects include elevated intraocular pressure, cataract, and injection related complications such as endophthalmitis, vitreous hemorrhage, and retinal detachment particularly with intravitreal steroid injections. In order to reduce the risks, complications and frequent dosing of intravitreal steroids, intravitreal implants have been developed recently to provide sustained release of corticosteroids and reduce repeated intravitreal injections for the management of DME.
    World journal of diabetes. 12/2013; 4(6):295-302.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: To describe changes of the foveal photoreceptor layer using optical coherence tomography (OCT) in diabetic macular edema (DME) treated with argon laser photocoagulation (ALP) or intravitreal triamcinolone (IVTA) and correlate these changes with visual outcome. DESIGN: Analysis of OCT images from a prospective randomised controlled trial of ALP versus IVTA for DME. METHODS: We studied the final OCT images of 71 eyes with diabetic macular edema. The tomographic finding of the foveal third hyper-reflective band (HRB) was classified into 2 groups: intact HRB and disrupted or absent HRB. The final visual outcome in these groups were compared in both the laser group and the IVTA group RESULTS: The presence of the third HRB at the fovea was associated with better visual outcome in both treatment groups with the laser group showing statistically significant correlation. CONCLUSION: Intact foveal third HRB is a reliable indicator of favourable final visual outcome following treatment of DME.